PVLA

Palvella Therapeutics (PVLA)

About Palvella Therapeutics (PVLA)

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. It develops a pipeline of treatments for rare genetic skin diseases using its patented QTORIN platform. The company was founded in 2015 and is headquartered in Wayne, PA.

Details

Daily high

$120.20

Daily low

$116.83

Price at open

$116.85

52 Week High

$151.18

52 Week Low

$20.35

Market cap

1.7B

Dividend yield

0.00%

Volume

151,458

Avg. volume

267,449

P/E ratio

-28.51

Palvella Therapeutics News